Financial Performance - The total operating revenue for 2025 reached RMB 54,210.81 million, representing a 71.23% increase compared to the previous year[3] - The net profit attributable to the parent company was RMB 8,062.19 million, marking a significant turnaround from a loss of RMB 4,359.62 million in the previous year[3] - The basic earnings per share increased to RMB 0.22 from a loss of RMB 0.12 in the previous year[3] - The weighted average return on net assets improved to 10.78%, an increase of 17.11 percentage points from -6.33% in the previous year[3] - Total assets at the end of the reporting period were RMB 94,561.27 million, up 20.77% from the beginning of the period[3] - The net profit attributable to the parent company and the net profit after deducting non-recurring gains and losses both saw substantial increases, indicating an optimized profit structure[7] Revenue Growth - The company’s international business revenue grew by over 130%, contributing to a significant increase in overall revenue[6] Product Innovation - The company successfully launched multiple innovative products that gained widespread clinical recognition, leading to increased hospital admissions and clinical usage[7] Cost Management - The company maintained effective control over costs and operating expenses, which contributed to the overall profitability turnaround[7] Research and Development - The company continues to invest in R&D, particularly in the fields of intelligent and precise interventional treatment, to drive long-term sustainable growth[6]
北芯生命(688712) - 2025 Q4 - 年度业绩